Cervical, breast and bowel screening (FOI)Cervical, breast and bowel screening (FOI)
Produced by the Freedom of Information officeAuthored by Government of Jersey and published on
24 November 2020.Prepared internally, no external costs.
Request
A
Please could you give numbers for how many people attended routine cervical screening appointments during each quarter of 2018, each quarter of 2019 and the three quarters (so far) of 2020?
B
During 2018, 2019 and the first nine months of 2020, how many of those screened, broken down by year, were reported as having abnormal changes in the cells of the cervix?
C
Please could you provide the equivalent numbers as above for bowel screening (broken down by quarters), and the numbers who required follow-up appointments or action? Or if simpler, the percentage of patients each year given an 'all clear' result.
D
Please could you provide the equivalent numbers for breast screening (broken down by quarters), and the numbers who required follow-up appointments or action? Or if simpler, the percentage of patients each year given an 'all clear' result.
Response
A
Table 1 shows the number of cervical cytology samples received by Health and Community Services (HCS) Pathology laboratory. Appointments are attended at GP practices, as well as the Well Woman Clinic run by HCS. GP data is not covered by Freedom of Information, therefore the only available figures to this question is the number of samples received in the laboratory.
Table 1: Number of Cervical Cytology samples received
βYear | βQ1 | βQ2 | Q3β | βQ4 |
β2018 | β1520 | β1348 | β1462 | β1485 |
β2019 | β1971 | β1854 | β1793 | β1466 |
β2020 | β1459 | β535 | β1526 | β- |
Please note that these figures include a relatively small number of samples that may have come from the same patient at different points in their screening recall cycle.
Some samples are taken whilst patients are under the care of the gynaecology team, and these are therefore not technically within the remit of the cervical screening programme. As these are not easily able to be identified, they are included in the figures.
B
Table 2 shows the number of cervical cytology samples reported as showing abnormal changes in the cells of the cervix.
Table 2: Number of Cervical Cytology samples showing abnormal changes in the cells of the cervix
β2018 | β241 |
β2019 | β284 |
β2020 Q1-Q3 | β168 |
C
When a person attends bowel screening, the outcome might be all clear, or polyps may be found but may be removed and sent for histology. People are recalled for a follow-up procedure if there are multiple or complex polyps or if the histology results show that further procedure is required.
Table 3 shows the number of people who attended bowel screening appointments by year and quarter. Table 4 shows the number of people who have undergone a follow-up procedure. The Department has determined that where numbers are less than five, to provide the specific number of appointments would likely breach the privacy of the individuals. Article 25 (Personal Information) of the Freedom of Information (Jersey) Law 2011 has therefore been applied.
Table 3: Number of People attending Bowel Screening
βYear | βQ1 | Q2β | Q3β | Q4β |
β2018 | β180 | β160 | β188 | β148 |
β2019 | β143 | 170β | β161 | β118 |
β2020 | β140 | β<5 | 28β | β- |
Please note that the service was suspended due to COVID restrictions, hence the low numbers in Q2 and Q3 2020.
Table 4: Number of people undergoing follow-up procedures
βYear | Q1β | Q2β | Q3β | Q4β |
β2018 | β7 | β12 | β11 | 15β |
β2019 | β14 | 14β | 10β | 6β |
β2020 | β5 | β<5 | β0 | β- |
D
Table 5 shows the number of people who attended breast screening appointments by year and quarter. Table 6 shows the number of people who have undergone a follow-up procedure.
Table 5: Number of People attending Breast Screening
βYear | Q1β | Q2β | Q3β | Q4β |
β2018 | β1364 | β1491 | β1913 | β1551 |
β2019 | β1243 | β1159 | β1346 | β1242 |
β2020 | β1119 | β113 | β597 | β- |
Table 6: Number of People who required follow-up procedures
Year | Q1β | Q2β | Q3β | Q4β |
β2018 | 47β | 40β | 49β | 48β |
β2019 | 40β | 38β | 47β | 51β |
β2020 | β44 | β5 | β42 | β- |
Articles Applied
Article 25 Personal information
(1) Information is absolutely exempt information if it constitutes personal data of which the applicant is the data subject as defined in the Data Protection (Jersey) Law 2018.
(2) Information is absolutely exempt information if β
(a) it constitutes personal data of which the applicant is not the data subject as defined in the Data Protection (Jersey) Law 2018; and
(b) its supply to a member of the public would contravene any of the data protection principles, as defined in that Law.
(3) In determining for the purposes of this Article whether the lawfulness principle in Article 8(1)(a) of the Data Protection (Jersey) Law 2018 would be contravened by the disclosure of information, paragraph 5(1) of Schedule 2 to that Law (legitimate interests) is to be read as if sub-paragraph (b) (which disapplies the provision where the controller is a public authority) were omitted.